Pasithea Therapeutics Corp. KTTA
Last close
0.58
2026-09-04
Market cap
$19.4M
2026-06-30 share count
52-week range
0.28 - 2.06
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-2.91
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $486.6K | $15.1K | — |
| Cost of revenue | — | — | — | $113.2K | $17.3K | — |
| Gross profit | — | — | — | $373.4K | -$2.2K | — |
| R&D | $8.0M | $7.2M | $8.1M | $2.7M | — | — |
| SG&A | $12.9M | $7.1M | $7.9M | $9.9M | $4.5M | — |
| Total operating expenses | — | — | — | $697.1K | — | — |
| Operating income | -$20.9M | -$14.2M | -$16.0M | -$12.6M | -$4.5M | — |
| Interest expense | — | — | — | $102 | $508 | — |
| Pre-tax income | -$20.4M | -$13.9M | -$15.5M | -$11.7M | -$2.2M | — |
| Net income | -$20.4M | -$13.9M | -$16.0M | -$13.9M | -$2.2M | — |
| EPS, basic | -2.91 | -12.69 | -0.42 | -1.76 | -0.21 | — |
| EPS, diluted | -2.91 | -12.69 | -0.42 | -1.76 | -0.21 | — |
| Shares, diluted (wtd. avg.) | $7.0M | $1.1M | $1.2M | $1.3M | $10.4M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $55.2M | $6.9M | $16.3M | $33.1M | $52.9M | $243.7K |
| Total current assets | $56.5M | $7.4M | $16.7M | $34.1M | $53.3M | $248.0K |
| Property, plant and equipment | — | $122.3K | $141.2K | $125.2K | $20.1K | — |
| Goodwill | — | $1.3M | $1.3M | $1.3M | — | — |
| Other intangibles | $2.9M | $7.3M | $7.9M | $8.6M | — | — |
| Total assets | $60.2M | $16.1M | $26.1M | $45.2M | $53.3M | $248.0K |
| Accounts payable | $1.1M | $1.1M | $2.6M | $1.5M | $447.3K | $6.6K |
| Total current liabilities | $5.0M | $1.1M | $2.6M | $1.9M | $447.3K | $6.6K |
| Total liabilities | $5.0M | $1.3M | $2.7M | $2.7M | $1.9M | $6.6K |
| Retained earnings | -$70.0M | -$49.6M | -$35.3M | -$19.4M | -$2.2M | -$41.0K |
| Total equity | $55.2M | $14.8M | $23.4M | $42.5M | $51.4M | $241.4K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$15.2M | -$13.9M | -$12.8M | -$11.9M | -$3.2M | — |
| Depreciation and amortisation | $32.4K | $18.9K | $18.3K | $5.1K | $1.4K | — |
| Stock-based compensation | $297.5K | $773.7K | $592.3K | $835.1K | $471.2K | — |
| Capital expenditure | — | — | $34.3K | $107.1K | $21.5K | — |
| Investing cash flow | $11.0K | — | $75.2K | -$2.3M | -$21.5K | — |
| Financing cash flow | $63.5M | $4.5M | -$3.7M | -$3.2M | $55.9M | — |
| Buybacks | — | — | $3.7M | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-036434.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |